Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study.
ACR20/50/70
Anti-TNF
DAPSA28
DAS28
Psoriatic arthritis
Work disability
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
07
05
2021
accepted:
23
08
2021
revised:
29
07
2021
pubmed:
4
9
2021
medline:
6
1
2022
entrez:
3
9
2021
Statut:
ppublish
Résumé
To understand change in work productivity, activity impairment, quality of life (QoL), and disease activity in patients with psoriatic arthritis (PsA) receiving anti-tumor necrosis factor (anti-TNF) treatment. One hundred twenty patients with PsA receiving anti-TNF therapy were recruited to this noninterventional, observational study. Work disability was assessed via the Work Productivity and Activity Impairment (WPAI) questionnaire and disease activity was calculated via the 28-joint Disease Activity Score using C-reactive protein (DAS28-CRP) and Disease Activity Index for Psoriatic Arthritis with 28 joints (DAPSA28) score. Patient-reported outcomes (PROs), from visual analog scores and Health Assessment Questionnaire-Disability Index scores, were evaluated to understand the clinical effectiveness at baseline and every 3 months until the month-9 final visit. The American College of Rheumatology (ACR)20/50/70 response criteria were assessed at month 9. A total of 120 patients (females, n = 73) were enrolled in the study. Mean (SD) age and disease duration were 41.6 ± 11.1 years and 6.9 ± 6.5 years, respectively. The most commonly used TNFα inhibitor was adalimumab (42.4%), followed by etanercept (25.8%). All WPAI questionnaire parameters were reduced at the follow-up visits compared with baseline (p < 0.001 for all). PROs and disease activity indicators (DAS28-CRP and DAPSA28) significantly improved during the course of anti-TNF treatments (p < 0.001 for all). Additionally, ACR20/50/70 responses were determined as 86.8%, 63.7%, and 41.8% of patients at the month-9 visit. The real-world data in PsA patients receiving anti-TNF treatment showed improvement in WPAI, QoL, and disease activity over 9 months of treatment. NCT02028169 Key Points • Psoriatic arthritis (PsA), with debilitating effects on quality of life, occurs mostly in young adults and has negative impacts on employment status and work productivity. • Early PsA diagnosis and treat-to-target treatment strategies aim to reduce pain and joint damage, as well as improve work productivity. • Real-world data on the impact of treatment with anti-tumor necrosis factor (anti-TNF) agents on work productivity in PsA in the literature is scarce. • Our study of real-world data in patients with PsA receiving anti-TNF treatment showed improvement in work productivity, as well as in clinical and patient-reported outcomes.
Identifiants
pubmed: 34477993
doi: 10.1007/s10067-021-05893-3
pii: 10.1007/s10067-021-05893-3
doi:
Substances chimiques
Antirheumatic Agents
0
Tumor Necrosis Factor Inhibitors
0
Tumor Necrosis Factor-alpha
0
Adalimumab
FYS6T7F842
Etanercept
OP401G7OJC
Banques de données
ClinicalTrials.gov
['NCT02028169']
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
85-94Informations de copyright
© 2021. International League of Associations for Rheumatology (ILAR).
Références
Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriatic arthritis. N Engl J Med 376(10):957–970. https://doi.org/10.1056/NEJMra1505557
doi: 10.1056/NEJMra1505557
pubmed: 28273019
Tucker LJ, Coates LC, Helliwell PS (2019) Assessing disease activity in psoriatic arthritis: a literature review. Rheumatol Ther 6(1):23–32. https://doi.org/10.1007/s40744-018-0132-4
doi: 10.1007/s40744-018-0132-4
pubmed: 30471015
Lubrano E, Scriffignano S, Perrotta FM (2019) TNF-alpha inhibitors for the six treatment targets of psoriatic arthritis. Expert Rev Clin Immunol 15(12):1303–1312. https://doi.org/10.1080/1744666x.2020.1685382
doi: 10.1080/1744666x.2020.1685382
pubmed: 31652079
Pukšić S, Bolton-King P, Sexton J, Michelsen B, Kvien TK, Berner Hammer H (2018) DAPSA and ultrasound show different perspectives of psoriatic arthritis disease activity: results from a 12-month longitudinal observational study in patients starting treatment with biological disease-modifying antirheumatic drugs. RMD Open 4(2):e000765. https://doi.org/10.1136/rmdopen-2018-000765
doi: 10.1136/rmdopen-2018-000765
pubmed: 30487999
pmcid: 6242028
Bagel J, Schwartzman S (2018) Enthesitis and dactylitis in psoriatic disease: a guide for dermatologists. Am J Clin Dermatol 19(6):839–852. https://doi.org/10.1007/s40257-018-0377-2
doi: 10.1007/s40257-018-0377-2
pubmed: 30117018
pmcid: 6267546
Tillett W, Shaddick G, Jobling A, Askari A, Cooper A, Creamer P, Clunie G, Helliwell PS, James J, Kay L, Korendowych E, Lane S, Packham J, Shaban R, Thomas ML, Williamson L, McHugh N (2017) Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritis. Rheumatology (Oxford) 56(4):603–612. https://doi.org/10.1093/rheumatology/kew433
doi: 10.1093/rheumatology/kew433
Palsson O, Love TJ, Gunnarsdottir AI, Gunnarsson PS, Runarsdottir EE, Krogh NS, Gudbjornsson B (2019) Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible. RMD Open 5(2):e000984. https://doi.org/10.1136/rmdopen-2019-000984
doi: 10.1136/rmdopen-2019-000984
pubmed: 31413869
pmcid: 6667974
Tsuruta N, Narisawa Y, Imafuku S, Ito K, Yamaguchi K, Miyagi T, Takahashi K, Fukamatsu H, Morizane S, Koketsu H, Yamaguchi M, Hino R, Nakamura M, Ohyama B, Ohata C, Kuwashiro M, Sato T, Saito K, Kaneko S, Yonekura K, Hayashi H, Yanase T, Morimoto K, Sugita K, Yanagihara S, Kikuchi S, Mitoma C, Nakahara T, Furue M, Okazaki F (2019) Cross-sectional multicenter observational study of psoriatic arthritis in Japanese patients: relationship between skin and joint symptoms and results of treatment with tumor necrosis factor-α inhibitors. J Dermatol 46(3):193–198. https://doi.org/10.1111/1346-8138.14745
doi: 10.1111/1346-8138.14745
pubmed: 30628100
van der Heijde D, Braun J, Rudwaleit M, Purcaru O, Kavanaugh AF (2018) Improvements in workplace and household productivity with certolizumab pegol treatment in axial spondyloarthritis: results to week 96 of a phase III study. RMD Open 4(1):e000659. https://doi.org/10.1136/rmdopen-2018-000659
doi: 10.1136/rmdopen-2018-000659
pubmed: 29670761
pmcid: 5903272
Black CM (2012) Sickness absence and musculoskeletal disorders. Rheumatology (Oxford) 51(2):204–205. https://doi.org/10.1093/rheumatology/ker323
doi: 10.1093/rheumatology/ker323
Short P, Jones AC, Walker D, Kavanaugh A, Moots RJ (2012) Working at arthritis. Rheumatology (Oxford) 51(2):201–203. https://doi.org/10.1093/rheumatology/ker415
doi: 10.1093/rheumatology/ker415
Beaton DE, Dyer S, Boonen A, Verstappen SM, Escorpizo R, Lacaille DV, Bosworth A, Gignac MA, Leong A, Purcaru O, Leggett S, Hofstetter C, Peterson IF, Tang K, Fautrel B, Bombardier C, Tugwell PS (2016) OMERACT filter evidence supporting the measurement of at-work productivity loss as an outcome measure in rheumatology research. J Rheumatol 43(1):214–222. https://doi.org/10.3899/jrheum.141077
doi: 10.3899/jrheum.141077
pubmed: 26329339
Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, Primdahl J, McGonagle DG, Aletaha D, Balanescu A, Balint PV, Bertheussen H, Boehncke WH, Burmester GR, Canete JD, Damjanov NS, Kragstrup TW, Kvien TK, Landewé RBM, Lories RJU, Marzo-Ortega H, Poddubnyy D, Rodrigues Manica SA, Schett G, Veale DJ, Van den Bosch FE, van der Heijde D, Smolen JS (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79(6):700–712. https://doi.org/10.1136/annrheumdis-2020-217159
doi: 10.1136/annrheumdis-2020-217159
pubmed: 32434812
Fransen J, van Riel PL (2009) The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am 35(4):745-757 vii-viii. https://doi.org/10.1016/j.rdc.2009.10.001
doi: 10.1016/j.rdc.2009.10.001
pubmed: 19962619
Michelsen B, Sexton J, Smolen JS, Aletaha D, Krogh NS, van der Heijde D, Kvien TK, Hetland ML (2018) Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints? Ann Rheum Dis 77(12):1736–1741. https://doi.org/10.1136/annrheumdis-2018-213463
doi: 10.1136/annrheumdis-2018-213463
pubmed: 30237203
Kalyoncu U BO, Oksuz MF, Kimyon G, Erden A, Yavuz S, Cetin G, Kucuksahin O, Kilic L, Omma A, Ozisler C, Solmaz D, Onat AM, Kisacik B, Ersozlu Bakirli D, Cinar M, Tufan A, Yildiz F, Mercan R, Kasifoglu T, Yilmazer B, Yilmaz S, Aksu K, Erten S, Sayarlioglu M, Dalkilic E, Akar S, Acikel C, Aydin Tufan M, Balkarli A, Kasapoglu-Gunal E, Senel S, Kobak S, Duruoz MT, Dogru A, Tarhan EF, Can M, Akyol L, Pehlevan S, Erbasan F, Arslan F, Kucuk A, Gonullu E, Kabasakal Y, Sahin M, Atakan N, Aydin SZ (2016) Dapsa-28 may be used instead of Dapsa-66/68 in psoriatic arthritis [abstract]. Arthritis Rheumatol 68(10):3689–3690. https://acrabstracts.org/abstract/dapsa-28-may-be-used-instead-of-dapsa-6668-in-psoriatic-arthritis/
Lee MP, Lii J, Jin Y, Desai RJ, Solomon DH, Merola JF, Kim SC (2018) Patterns of systemic treatment for psoriatic arthritis in the US: 2004–2015. Arthritis Care Res (Hoboken) 70(5):791–796. https://doi.org/10.1002/acr.23337
doi: 10.1002/acr.23337
Perrotta FM, Marchesoni A, Lubrano E (2016) Minimal disease activity and remission in psoriatic arthritis patients treated with anti-TNF-α drugs. J Rheumatol 43(2):350–355. https://doi.org/10.3899/jrheum.150805
doi: 10.3899/jrheum.150805
pubmed: 26669925
Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665–2673. https://doi.org/10.1002/art.21972
doi: 10.1002/art.21972
pubmed: 16871531
Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4(5):353–365. https://doi.org/10.2165/00019053-199304050-00006
doi: 10.2165/00019053-199304050-00006
pubmed: 10146874
Klaudius I, Krueger K, Remstedt S, Thiele A (2018) SAT0187 Golimumab improves work productivity and activity impairment in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PSA): 1-year results from a non- interventional trial in Germany. Ann Rheum Dis 77(Suppl 2):954–955. https://doi.org/10.1136/annrheumdis-2018-eular.2925
doi: 10.1136/annrheumdis-2018-eular.2925
Mease P (2020) Enthesitis in psoriatic arthritis (Part 3): clinical assessment and management. Rheumatology (Oxford) 59(Supplement_1):i21–i28. https://doi.org/10.1093/rheumatology/keaa042
doi: 10.1093/rheumatology/keaa042
Kavanaugh A, Mease P (2012) Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL). J Rheumatol Suppl 89:90–93. https://doi.org/10.3899/jrheum.120254
doi: 10.3899/jrheum.120254
pubmed: 22751603
Schoels MM, Aletaha D, Alasti F, Smolen JS (2016) Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 75(5):811–818. https://doi.org/10.1136/annrheumdis-2015-207507
doi: 10.1136/annrheumdis-2015-207507
pubmed: 26269398
Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A (2005) Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64(8):1150–1157. https://doi.org/10.1136/ard.2004.032268
doi: 10.1136/ard.2004.032268
pubmed: 15677701
pmcid: 1755609
Mease PJ, Ory P, Sharp JT, Ritchlin CT, Van den Bosch F, Wellborne F, Birbara C, Thomson GT, Perdok RJ, Medich J, Wong RL, Gladman DD (2009) Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 68(5):702–709. https://doi.org/10.1136/ard.2008.092767
doi: 10.1136/ard.2008.092767
pubmed: 18684743
Gladman DD, Sampalis JS, Illouz O, Guérette B (2010) Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study. J Rheumatol 37(9):1898–1906. https://doi.org/10.3899/jrheum.100069
doi: 10.3899/jrheum.100069
pubmed: 20595284
Kavanaugh A, McInnes IB, Krueger GG, Gladman D, Beutler A, Gathany T, Mack M, Tandon N, Han C, Mease P (2013) Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken) 65(10):1666–1673. https://doi.org/10.1002/acr.22044
doi: 10.1002/acr.22044
Gladman D, Fleischmann R, Coteur G, Woltering F, Mease PJ (2014) Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study. Arthritis Care Res (Hoboken) 66(7):1085–1092. https://doi.org/10.1002/acr.22256
doi: 10.1002/acr.22256
Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J (2005) Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52(4):1227–1236. https://doi.org/10.1002/art.20967
doi: 10.1002/art.20967
pubmed: 15818699
Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT, Mease PJ, Gladman DD, de Vlam K, Geusens PP, Birbara C, Halter DG, Antoni C (2007) Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 66(4):498–505. https://doi.org/10.1136/ard.2006.058339
doi: 10.1136/ard.2006.058339
pubmed: 17114188
Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356(9227):385–390. https://doi.org/10.1016/s0140-6736(00)02530-7
doi: 10.1016/s0140-6736(00)02530-7
pubmed: 10972371
Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A (2009) Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60(4):976–986. https://doi.org/10.1002/art.24403
doi: 10.1002/art.24403
pubmed: 19333944
Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D, Woltering F, Stach C, Hoepken B, Arledge T, van der Heijde D (2014) Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 73(1):48–55. https://doi.org/10.1136/annrheumdis-2013-203696
doi: 10.1136/annrheumdis-2013-203696
pubmed: 23942868
Damjanov N, Karpati S, Kemeny L, Bakos N, Bobic B, Majdan M, Tlustochowicz W, Vitek P, Dokoupilova E, Aldinc E, Szumski A (2018) Efficacy and safety of etanercept in psoriasis and psoriatic arthritis in the PRESTA study: analysis in patients from Central and Eastern Europe. J Dermatolog Treat 29(1):8–12. https://doi.org/10.1080/09546634.2017.1329509
doi: 10.1080/09546634.2017.1329509
pubmed: 28506134
Kalyoncu U, Bayindir Ö, Ferhat Öksüz M, Doğru A, Kimyon G, Tarhan EF, Erden A, Yavuz Ş, Can M, Çetin GY, Kılıç L, Küçükşahin O, Omma A, Ozisler C, Solmaz D, Bozkirli ED, Akyol L, Pehlevan SM, Gunal EK, Arslan F, Yılmazer B, Atakan N, Aydın SZ (2017) The Psoriatic Arthritis Registry of Turkey: results of a multicentre registry on 1081 patients. Rheumatology (Oxford) 56(2):279–286. https://doi.org/10.1093/rheumatology/kew375
doi: 10.1093/rheumatology/kew375
Bhutani T, Wong JW, Bebo BF, Armstrong AW (2013) Access to health care in patients with psoriasis and psoriatic arthritis: data from National Psoriasis Foundation survey panels. JAMA Dermatol 149(6):717–721. https://doi.org/10.1001/jamadermatol.2013.133
doi: 10.1001/jamadermatol.2013.133
pubmed: 23783152
Ayan G, Aydin SZ, Kimyon G, Ozisler C, Tinazzi I, Dogru A, Omma A, Kilic L, Yılmaz S, Kucuksahin O, Gönüllü E, Yıldız F, Can M, Balkarlı A, Solmaz D, Dalkılıc E, Bayindir O, Yıldırım Çetin G, Ergulu Esmen S, Ersozlu ED, Duruoz MT, Akyol L, Kucuk A, Bes C, Cınar M, Erden A, Mercan R, Bakirci S, Kasifoglu T, Yazısız V, Kalyoncu U (2021) PsART-ID inception cohort: clinical characteristics, treatment choices and outcomes of patients with psoriatic arthritis. Rheumatology (Oxford) 60(4):1755–1762. https://doi.org/10.1093/rheumatology/keaa663
doi: 10.1093/rheumatology/keaa663